financetom
Business
financetom
/
Business
/
Private equity owner of Dr. Squatch explores $2 bln-plus sale of personal care brand, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Private equity owner of Dr. Squatch explores $2 bln-plus sale of personal care brand, sources say
Apr 3, 2024 1:42 PM

NEW YORK, April 3 (Reuters) - The private equity owner

of Dr. Squatch is exploring a sale of the men's grooming brand

that it hopes will value the company at more than $2 billion,

people familiar with the matter said on Wednesday.

The company, which is majority-owned by Summit Partners, is

working with investment banks Raymond James and Centerview

Partners to gauge interest from potential buyers, the sources

said, requesting anonymity as the discussions are confidential.

Dr. Squatch currently generates 12-month earnings before

interest, taxes, depreciation and amortization (EBITDA) of about

$90 million and is growing rapidly, the sources said.

Dr. Squatch, Summit Partners, and Raymond James did not

immediately respond to requests for comment. Centerview declined

to comment.

Launched in 2013 by founder and CEO Jack Haldrup and named

after the mythical creature Sasquatch, Dr. Squatch started out

by selling handmade bar soaps for men. Haldrup created his own

soap flavors out of his garage because natural soap for men is

not widely produced by major personal care brands.

The Los Angeles-based company currently sells deodorant,

hair care products, colognes, lotions and other personal care

products through its website and at brick-and-mortar stores like

Walmart ( WMT ) and Target ( TGT ).

Dr. Squatch is known for its Super Bowl ads targeting men

and unique scents like cold brew cleanse and grapefruit IPA.

The personal care segment has been a bright spot for

dealmaking over the past year. Carlyle-owned grooming brand

Every Man Jack has been exploring a sale, while Unilever ( UL ) agreed

to sell one of its men's personal care brands, Dollar Shave

Club, to private-equity firm Nexus Capital Management last year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
-- Onex Brief: Partnering to Acquire Integrated Specialty Coverages
-- Onex Brief: Partnering to Acquire Integrated Specialty Coverages
Sep 19, 2025
02:31 PM EDT, 09/18/2025 (MT Newswires) -- Price: 123.29, Change: +0.94, Percent Change: +0.77 ...
Utz Brands to Upgrade Hanover Campus; Shares Rise
Utz Brands to Upgrade Hanover Campus; Shares Rise
Sep 19, 2025
02:45 PM EDT, 09/18/2025 (MT Newswires) -- Utz Brands ( UTZ ) said Thursday it plans to upgrade facilities in its Hanover, Pennsylvania, campus. Under the multi-phase project, construction will begin in 2026 to overhaul the company's headquarters at 900 High Street into an employee hub. The company will also relocate its fitness center and DSD warehouse to the campus....
Thomson Reuters, Supio Form Partnership to Scale AI for Personal Injury Law Firms
Thomson Reuters, Supio Form Partnership to Scale AI for Personal Injury Law Firms
Sep 19, 2025
02:45 PM EDT, 09/18/2025 (MT Newswires) -- Thomson Reuters ( TMSOF ) and Supio formed a partnership that will allow Thomson Reuters ( TMSOF ) clients to leverage Supio's CaseAware AI platform and utilize AI-powered case preparation tools, Supio said Thursday. According to Supio, the platform streamlines case preparation by automating the review process of medical records, which can help...
Intellia Therapeutics Shares Are Ripping Higher: Here's Why
Intellia Therapeutics Shares Are Ripping Higher: Here's Why
Sep 19, 2025
Intellia Therapeutics Inc ( NTLA ) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones. What Happened:  Intellia announced that it concluded patient enrollment in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) within nine months of dosing the first subject. Phase 3...
Copyright 2023-2026 - www.financetom.com All Rights Reserved